Inhibition of histone deacetylase 6 restores intestinal tight junction in hemorrhagic shock.

Background: We recently discovered that Tubastatin-A, histone deacetylase (HDAC6) inhibitor, can improve survival in a rodent model of hemorrhagic shock (HS), but mechanisms remain poorly defined. In this study we investigated whether Tubastatin-A could protect intestinal tight junction (TJ) in HS. Methods: In-vivo study: Wistar-Kyoto rats underwent HS (40% blood loss) followed by Tubastatin-A (70 mg/kg) treatment, without fluid resuscitation. The experimental groups were: (1) sham (no hemorrhage, no treatment), (2) control (hemorrhage, without treatment), and (3) treatment (hemorrhage with Tubastatin-A administration). Three hours after hemorrhage, ileum was harvested. Whole cell lysate were analyzed for acetylated [alpha]-tubulin (Ac-tubulin), total tubulin, acetylated histone 3 at lysine 9 (Ac-H3K9), [beta]-actin, claudin-3 and zonula occludens 1 (ZO-1) proteins by western blot. Histological effects of Tubastatin-A on small bowel were examined. In-vitro study: human intestinal epithelial cells (Caco-2) were divided into 3 groups: (1) sham (normoxia), (2) control (anoxia, no treatment), (3) treatment (anoxia, treatment with Tubastatin-A). After 12 hours in a anoxia chamber, the cells were examined for Ac-tubulin and Ac-H3K9, cellular viability, cytotoxicity, claudin-3 and ZO-1 protein expression, and transwell permeability study. Results: Tubastatin-A treatment significantly attenuated HS-induced decreases of Ac-tubulin, Ac-H3K9, ZO-1 and claudin-3 proteins in small bowel in-vivo (P

from Emergency Medicine via xlomafota13 on Inoreader http://ift.tt/1t7QEFJ